{
    "root": "30a15778-abf6-7ff2-e063-6294a90ac702",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Simvastatin",
    "value": "20250318",
    "ingredients": [
        {
            "name": "ASCORBIC ACID",
            "code": "PQ6CK8PD0R"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "SIMVASTATIN",
            "code": "AGG2FN16EV"
        }
    ],
    "indications": "Simvastatin tablets USP are indicated:\n                  \n                     To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.\n                     As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C):\n  \n   \n                           In adults with primary hyperlipidemia.\n                           In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                        \n                     \n                     As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the treatment of adults with:\n  \n   \n                           Primary dysbetalipoproteinemia.\n                           Hypertriglyceridemia.",
    "contraindications": "Important Dosage and Administration Information : (2.1) Take simvastatin tablets USP orally once daily in the evening. Maximum recommended dosage is simvastatin tablets USP 40 mg once daily. An 80 mg daily dosage of simvastatin tablets USP is restricted to patients who have been taking simvastatin tablets USP 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving simvastatin tablets USP 40 mg daily, prescribe alternative LDL-C lowering treatment. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating, and adjust the dosage if necessary. Adults : Recommended dosage is 20 mg to 40 mg once daily. (2.2) Pediatric Patients Aged 10 Years and Older with HeFH : Recommended dosage is 10 mg to 40 mg once daily. (2.3) Patients with Severe Renal Impairment : Recommended starting dosage is simvastatin 5 mg once daily. (2.4 , 8.6) See full prescribing information for simvastatin tablets USP dosage modifications due to drug interactions. (2.5)",
    "warningsAndPrecautions": "Simvastatin Tablets USP, 10 mg are peach colored, oval shaped, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C02' on the other side. They are supplied as follows:\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-511-01\n \n                  Simvastatin Tablets USP, 20 mg are tan colored, oval shaped, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C03' on the other side. They are supplied as follows:\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-512-01\n \n                  Simvastatin Tablets USP, 40 mg are brick red colored, round shaped, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C04' on the other side. They are supplied as follows:\n  \nUnit dose packages of 100 (10 x 10) NDC 60687-210-01\n \n                  \n                     Storage\n                     \nStore between 20째 to 25째C (68째 to 77째F) [See USP Controlled Room Temperature].\n \n                  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.",
    "adverseReactions": "Simvastatin is contraindicated in the following conditions:\n                  \n                     Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone)\n  \n   [see\n   \n    DRUG INTERACTIONS (7.1)].\n  \n   \n                     \n                     Concomitant use of cyclosporine, danazol or gemfibrozil\n  \n   [see\n   \n    DRUG INTERACTIONS (7.1)].\n  \n   \n                     \n                     Acute liver failure or decompensated cirrhosis\n  \n   [see\n   \n    WARNINGS AND PRECAUTIONS (5.3)]\n  \n   \n                     \n                     Hypersensitivity to simvastatin or any excipients in simvastatin tablets USP. Hypersensitivity reactions, including anaphylaxis, angioedema and Stevens-Johnson syndrome, have been reported\n  \n   [see\n   \n    ADVERSE REACTIONS (6.2)]"
}